# CRD-38 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/crd-38

> The next catalyst for CRD-38, sponsored by Cardiol Therapeutics Inc. (CRDL), is its topline data readout, mid-2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for CRD-38?

The next catalyst for CRD-38, sponsored by Cardiol Therapeutics Inc. (CRDL), is its topline data readout, mid-2027. Press release filed with the SEC (EX-99): "Topline results are anticipated in mid-2027, following completion of expanded enrollment and the required patient follow-up." [Calendar and source filings](https://sec-api.dev/pdufa/crd-38)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-126269, https://www.sec.gov/Archives/edgar/data/1702123/000110465926126269/tm2629596d1_ex99-2.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/crd-38#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | CRD-38 |
| Codes | CRD-38 |
| Sponsor | Cardiol Therapeutics Inc. (CRDL) https://sec-api.dev/companies/crdl/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jun 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-11-13, last confirmed 2026-08-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-094885): "In June 2024, the Corporation reported positive topline 8-week clinical data from its MAvERIC-Phase II study and in November 2024, the Corporation reported comprehensive MAvERIC-Phase" https://www.sec.gov/Archives/edgar/data/1702123/000110465926094885/tm2622666d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058766): "In June 2024, the Corporation reported positive topline 8-week clinical data from its MAvERIC-Phase II study and in November 2024, the Corporation reported comprehensive MAvERIC-Phase" https://www.sec.gov/Archives/edgar/data/1702123/000110465926058766/tm2614096d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-111354): "In June 2024, the Corporation reported positive topline 8-week clinical data from its MAVERIC-Phase II study and in November 2024, the Corporation reported comprehensive MAVERIC-Phase" https://www.sec.gov/Archives/edgar/data/1702123/000110465925111354/tm2530953d1_ex99-2.htm

### mid-2027: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-09-23, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-126269): "Topline results are anticipated in mid-2027, following completion of expanded enrollment and the required patient follow-up." https://www.sec.gov/Archives/edgar/data/1702123/000110465926126269/tm2629596d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001279569-26-000905): "Topline results anticipated in mid-2027 following expanded enrollment and study completion." https://www.sec.gov/Archives/edgar/data/1702123/000127956926000905/ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001279569-26-000905): "Topline results are now anticipated in mid-2027, compared with our previous Q1 2027 guidance." https://www.sec.gov/Archives/edgar/data/1702123/000127956926000905/ex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/crd-38.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CRD-38 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/crd-38

```bibtex
@misc{secapidev_pdufa_crd_38_20261116,
  title        = {CRD-38 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/crd-38}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_crd_38_20261116","title":"CRD-38 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/crd-38","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
